v3.26.1
Segment reporting (Schedule of reconciliation to consolidated operating expenses) (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Salaries and benefits $ 568,329   $ 356,641   $ 1,527,207 $ 875,169
Total research and development expenses 4,907,692   1,439,564   7,612,085 3,445,778
Total general and administrative expenses 6,571,097   4,576,524   12,463,781 7,696,584
Total operating expenses 11,478,789   6,016,088   20,075,866 11,142,362
Other income (expense):            
Finance income 0   40,004   0 63,870
Interest income (expense) (205,638)   0   (523,789) 0
Loss on SEPA settlements 0   0   (127,083) 0
Change in fair value of debentures 0   (200,000)   0 (200,000)
Total other income (expense) (205,638)   (159,996)   (650,872) (136,130)
Net loss for the period (11,684,427) $ (9,042,311) (6,176,084) $ (5,102,408) (20,726,738) (11,278,492)
SkinJect [Member] | Clinical, manufacturing and regulatory activities [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Research and development expenses 1,268,747   1,011,362   2,011,288 2,453,931
SkinJect [Member] | Professional services and intellectual property [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Research and development expenses 96,653   71,561   145,227 116,678
Teverelix [Member] | Clinical, manufacturing and regulatory activities [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Research and development expenses 2,927,793   0   3,850,023 0
Teverelix [Member] | Professional services and intellectual property [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Research and development expenses $ 46,169   $ 0   $ 78,341 $ 0